Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

231.52
-0.8300-0.36%
Post-market: 227.76-3.7600-1.62%19:30 EDT
Volume:1.00M
Turnover:233.31M
Market Cap:15.03B
PE:15.83
High:236.00
Open:231.60
Low:230.39
Close:232.35
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.24
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.13
PE(LYR):-39.64

Loading ...

Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next

Simply Wall St.
·
Sep 02

Jazz Pharma EVP Global Head of R&D and CMO Robert Iannone Disposes of Shares Worth $19.23 Million

Reuters
·
Sep 01

Jazz Pharmaceuticals Unit Launches Private Offering of $1 Billion Exchangeable Senior Notes Due 2032

Reuters
·
Sep 01

Jazz Says FDA Approves Ziihera Combos for First-Line HER2+ Advanced Gastroesophageal Cancer

Reuters
·
Aug 31

Ziihera® (Zanidatamab-Hrii) Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab Plus Chemotherapy in First-Line Her2+ Advanced Gea

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Herizon-Gea-01 Results Reinforce Ziihera as Definitive Her2-Targeted Backbone in First-Line Gea

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Contains Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Ziihera Plus Tislelizumab and Chemotherapy Improves Os Hazard Ratio, Supporting New Standard of Care

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals: Safety Profile of Ziihera in Combination with Chemotherapy Generally Consistent with Known Safety Profile

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera

Simply Wall St.
·
Aug 30

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

MT Newswires Live
·
Aug 28

RBC Raises Price Target on Jazz Pharmaceuticals to $299 From $277, Keeps Outperform Rating

MT Newswires Live
·
Aug 28

Jazz Pharmaceuticals Plc : RBC Raises Target Price to $299 from $277

THOMSON REUTERS
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Jazz Pharmaceuticals prices upsized $1.1B offering of exchangeable senior notes

TIPRANKS
·
Aug 27

Jazz Pharmaceuticals (JAZZ) Stock May Be Undervalued As FDA Cancer Approval Lands

Simply Wall St.
·
Aug 27

Jazz Pharmaceuticals Prices Upsized $1.1 Billion Senior Notes Offering

MT Newswires Live
·
Aug 27

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 27

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
Aug 27

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 27